Follow-Up for Testicular Cancer

  • Christian G. RufEmail author
Living reference work entry


There are some specifics in testis cancer patients compared to other tumor entities. The excellent cure rates, even in advanced tumor disease, the young age, and the broad-spectrum of treatment options including reduction in treatment intensity lead to a long life expectancy with different rates of tumor relapse and side effects. Follow-up in testis cancer is worthwhile; cure rates are high even in relapsed disease. Follow-up should be frequent enough to detect relapse and side effects early enough to treat it and seldom enough to be feasible and not to harm patients, e.g., by exposure against ionizing radiation.

Therefore, anamnesis, clinical examination, different imaging procedures, and blood test should be done. Follow-up schedules are adapted to histology, clinical stage, and treatment modalities. Additionally, personalization of follow-up for some patients is essential, especially due to the broad-spectrum of side effect. In the vast majority of testicular cancer patients, a follow-up for 5–10 years and above is needful.


  1. Abouassaly R, Fosså SD, Giwercman A, Kollmannsberger C, Motzer RJ, Schmoll HJ, Sternberg CN. Sequelae of treatment in long-term survivors of testis cancer. Eur Urol. 2011;60:516–26.CrossRefGoogle Scholar
  2. Albers P, Siener R, Kliesch S, Weissbach L, Krege S, Sparwasser C, Schulze H, Heidenreich A, de Riese W, Loy V, Bierhoff E, Wittekind C, Fimmers R, Hartmann M, German Testicular Cancer Study Group. Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: results of the German Testicular Cancer Study Group Trial. J Clin Oncol. 2003;21(8):1505–12.Google Scholar
  3. Albers P, Siener R, Krege S, Schmelz HU, Dieckmann KP, Heidenreich A, Kwasny P, Pechoel M, Lehmann J, Kliesch S, Köhrmann KU, Fimmers R, Wessbach L, Loy V, Wittekind C, Hartmann M. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of stage I nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group. J Clin Oncol. 2008;26(18):2966–72.CrossRefGoogle Scholar
  4. Albers P, et al. Maligne Hodentumoren. In: Rübben H, editor. Uroonkologie. Berlin/Heidelberg: Springer; 2014.Google Scholar
  5. Aparicio J, Maroto P, del Muro XG, Gumà J, Sánchez-Muñoz A, Margelí M, Doménech M, Bastús R, Fernández A, López-Brea M, Terrassa J, Meana A, del Prado PM, Sastre J, Satrústegui JJ, Gironés R, Robert L, Germà JR. Risk-adapted treatment in clinical stage I testicular seminoma: the third Spanish Germ Cell Cancer Group study. J Clin Oncol. 2011;29(35): 4677–81. Scholar
  6. Bokemeyer C, Nowak P, Haupt A, Metzner B, Köhne H, Hartmann JT, Kanz L, Schmoll HJ. Treatment of brain metastasis in patients with testicular cancer. J Clin Oncol. 1997;15:1449–54.CrossRefGoogle Scholar
  7. Buchler T, Kubankova P, Boublikova L, et al. Detection of second malignancies during long-term follow-up of testicular cancer survivors. Cancer. 2011;117(18): 4212–8.CrossRefGoogle Scholar
  8. Cathomas R, Hartmann M, Krege S, Souchon R, Lorch A, Mayer F, De Santis M, Gillessen S. Interdisciplinary evidence-based recommendations for the follow-up of testicular germ cell cancer patients. Onkologie. 2011;34:59–64.CrossRefGoogle Scholar
  9. Classen J, Schmidberger H, Meisner C, Souchon R, Sautter-Bihl ML, Sauer R, Weinknecht S, Köhrmann U, Bamberger M. Radiotherapy for stage IIA/B testicular seminoma: final report of a prospective multicenter clinical trial. J Clin Oncol. 2003;21(6):1101–6.CrossRefGoogle Scholar
  10. Classen J, Souchon R, Hehr T, Hartmann M, Hartmann JT, Bamberg M. Posttreatment surveillance after paraaortic radiotherapy for stage I seminoma: a systematic analysis. J Cancer Res Clin Oncol. 2010;136(2):227–32.CrossRefGoogle Scholar
  11. Cost NG, Adibi M, Lubahn JD, Romman A, Raj GV, Sagalowski AI, Margulis V. Effect of testicular germ cell tumor therapy on renal function. Urology. 2012; 80(3):641–8.CrossRefGoogle Scholar
  12. De Felice F, Musio D, Gravina GL, Marampon F, Tombolini V. Adjuvant radiation therapy in stage I seminoma: 20 years of oncologic results. Oncotarget. 2016;7(48):80077–82.
  13. De La Pena H, Sharma A, Glicksman C, Joseph J, Subesinghe M, Traill Z, Verrill C, Sullivan M, Redgwell J, Bataillard E, Pintus E, Dallas N, Gogbashian A, Tuthill M, Protheroe A, Hall M. No longer any role for routine follow-up chest X-rays in men with stage I germ cell cancer. Eur J Cancer. 2017;84:354–9.Google Scholar
  14. De Wit R, Roberts JT, Wilkinson PM, de Mulder PH, Mead GM, Fosså SD, Cook P, de Prijck L, Stenning S, Collette L. Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol. 2001; 19(6):1629–40.Google Scholar
  15. Dieckmann KP, Classen J, Loy V. Diagnosis and management of testicular intraepithelial neoplasia (carcinoma in situ) – surgical aspects. APMIS. 2003;111(1):64–8.CrossRefGoogle Scholar
  16. Dieckmann KP, Albers P, Classen J, De Wit M, Pichlmeier U, Rick O, Müllerleile U, Kuczyk M. Late relapse of testicular germ cell neoplasms: a descriptive analysis of 122 cases. J Urol. 2005;173(3):824–9.CrossRefGoogle Scholar
  17. Dieckmann KP, Anheuser P, Sattler F, Von Kügelgen T, Matthies C, Ruf C. Sequential bilateral testicular tumours presenting with intervals of 20 years and more. BMC Urol. 2013;13:71.
  18. Dieckmann KP, Dralle-Filiz I, Matthies C, Heinzelbecker J, Bedke J, Ellinger J, Anheuser P, Souchon R, Pichlmeier U, German Testicular Cancer Study Group. Testicular seminoma clinical stage 1: treatment outcome on a routine care level. J Cancer Res Clin Oncol. 2016;142(7):1599–607. Scholar
  19. Dieckmann KP, Radtke A, Spiekermann M, Balks T, Matthies C, Becker P, Ruf C, Oing C, Oechsle K, Bokemeyer C, Hammel J, Melchior S, Wosniok W, Belge G. Serum levels of microRNA miR-371a-3p: a sensitive and specific new biomarker for germ cell tumours. Eur Urol. 2017;71(2):213–20. Scholar
  20. EAU Guidelines on Testicular cancer (2018) Presented at the EAU Annual Congress Copenhagen 2018. ISBN 978-94-92671-01-1.Google Scholar
  21. Flechon A, Culine S, Theodore C, Droz J-P. Pattern of relapse after first line treatment of advanced stage germ-cell tumors. Eur Urol. 2005;48:957–64.CrossRefGoogle Scholar
  22. Fosså SD. Long-term sequelae after cancer therapy – survivorship after treatment for testicular cancer. Acta Oncol. 2004;43:134–41.CrossRefGoogle Scholar
  23. Gerl A, Clemm C, Schmeller N, Hartenstein R, Lamerz R, Willmanns W. Prognosis after salvage treatment for unselected male patients with germ cell tumours. Br J Cancer. 1995;72:1026–32.CrossRefGoogle Scholar
  24. Gerl A, Barba M, Weiss M, Liedl B, Zimmermann F, Clemm C. Hodentumoren. Manual Urogenitale Tumoren. Tumorzentrum München u. Zuckschwerdt, München (article in german). 2003.Google Scholar
  25. Gilligan T. Testicular cancer survivorship. Hematol Oncol Clin North Am. 2011;25:627–39.CrossRefGoogle Scholar
  26. Hartmann M, Krege S, Souchon R, De Santis M, Gillessen S, Cathomas R. Nachsorge von Hodentumoren. Interdisziplinäre evidenzbasierte Empfehlungen. Urologe. 2011;50:830–5.CrossRefGoogle Scholar
  27. Haugnes HS, Bosl GJ, Boer H, Gietema JA, Brydoy M, Oldenburg J, Dahl AA, Bremnes RM, Fosså SD. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. J Clin Oncol. 2012;30:3752–63.CrossRefGoogle Scholar
  28. International Germ Cell Cancer Collaborative Group (IGCCCG). The International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancer. J Clin Oncol. 1997; 15:594–603.CrossRefGoogle Scholar
  29. Jewett MAS, Grabowski A, McKiernan J. Management of recurrence and follow-up for cancer. Urol Clin N Am. 2003;30:819–30.CrossRefGoogle Scholar
  30. Krege S, Beyer J, Souchon R, Albers P, Albrecht E, et al. European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG). Part I and II. Eur Urol. 2008;53:478–513.CrossRefGoogle Scholar
  31. Nayan M, Jewett MA, Hosni A, Anson-Cartwright L, Bedard PL, Moore M, Hansen AR, Chung P, Warde P, Sweet J, O’Malley M, Atenafu EG, Hamilton RJ. Conditional risk of relapse in surveillance for clinical stage I testicular cancer. Eur Urol. 2017;71(1):120–7.CrossRefGoogle Scholar
  32. Nord C, Bjoro T, Ellingsen D, et al. Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicular cancer. Eur Urol. 2003;44:322–8.CrossRefGoogle Scholar
  33. Oechsle K, Bokemeyer C, Kollmannsberger C, Mayer F, Berger LA, Oing C, Honecher F. Bone metastases in germ cell tumor patients. J Cancer Res Clin Oncol. 2012;138(6):947–52.CrossRefGoogle Scholar
  34. Oldenburg J, Martin J, Fosså SD. Late relapse of germ cell malignancies: incidence, management and prognosis. J Clin Oncol. 2006;24:5508–11.CrossRefGoogle Scholar
  35. Oliver RTD, Ong J, Shamash J, Ravi R, Nagund V, Harper P, Ostrowski MJ, Sizer B, Levay MJ, Robinson A, Neal DE, Williams M. Long-term follow-up of Anglian Germ Cell Cancer Group: surveillance versus patients with stage I nonseminoma treated with adjuvant chemotherapy. Urology. 2004; 63(3):556–61.CrossRefGoogle Scholar
  36. Oliver RT, Mead GM, Rustin GJ, Joffe JK, Aass N, Coleman R, Gabe R, Pollock P, Stenning SP. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol. 2011;29(8):957–62. Scholar
  37. Richiardi L, Scelo G, Bofetta B, et al. Second malignancies among survivors of germ-cell testicular cancer: a pooled analysis between 13 cancer registries. Int J Cancer. 2007;120:623–31.CrossRefGoogle Scholar
  38. Rustin GJ, Mead GM, Sally P, et al. Randomized trial of two or five computed tomography scans in the surveillance of patients with stage I nonseminomatous germ cell tumors of the testis: Medical Research Council Trial TE08, ISRCTN56475197 – the National Cancer Research Institute Testis Cancer Clinical Studies Group. J Clin Oncol. 2007;10:1310–5.CrossRefGoogle Scholar
  39. Sohaib SA, Koh DM, Barbachano Y, Parikh J, Husband JE, Dearnaley DP, Horwich A, Huddart R. Prospective assessment of MRI for imaging retroperitoneal metastases from testicular germ cell tumours. Clin Radiol. 2009;64:362–7.CrossRefGoogle Scholar
  40. Souchon R, Hartmann M, Krege S, Lorch A, Mayer F, De Santis M, Gillessen S, Beyer J, Cathomas R. Interdisciplinary evidence-based recommendations for the follow-up of early stage seminomatous testicular germ cell cancer patients. Strahlenther Onkol. 2011; 187:158–66.CrossRefGoogle Scholar
  41. Spermon JR, Kiemeney LA, Meulemann EJ, Ramos L, Wetzels AM, Witjes JA. Fertility in men with testicular germ cell tumors. Fertil Steril. 2003;79(Suppl 3): 1543–9.CrossRefGoogle Scholar
  42. Tandstad T, Dahl O, Cohn-Cedermark G, Cavallin-Stahl E, Stiener U, Sollberg A, Langberg C, Bremnes RM, Laurell A, Wijkstrom H, Klepp O. Risk-adapted treatment in clinical stage I nonseminomatous germ cell cancer: the SWENOTECA management program. J Clin Oncol. 2009;27:2122–8.CrossRefGoogle Scholar
  43. Tandstad T, Smaaland R, Solberg A, Bremnes RM, Langberg CW, Laurell A, Stierner UK, Ståhl O, Cavallin-Ståhl EK, Klepp OH, Dahl O, Cohn-Cedermark G. Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish Norwegian Testicular Cancer Study Group. J Clin Oncol. 2011;29(6):719–25. Scholar
  44. Tandstad T, Ståhl O, Dahl O, Haugnes HS, Håkansson U, Karlsdottir Å, Kjellman A, Langberg CW, Laurell A, Oldenburg J, Solberg A, Söderström K, Stierner U, Cavallin-Ståhl E, Wahlqvist R, Wall N, Cohn-Cedermark G, SWENOTECA. Treatment of stage I seminoma, with one course of adjuvant carboplatin or surveillance, risk-adapted recommendations implementing patient autonomy: a report from the Swedish and Norwegian Testicular Cancer Group (SWENOTECA). Ann Oncol. 2016;27(7):1299–304.CrossRefGoogle Scholar
  45. Travis LB, Curtis RE, Storm H, et al. Risk of second malignant neoplasms among long-term survivors of testicular cancer. J Natl Cancer Inst. 1997;89:1429–39.CrossRefGoogle Scholar
  46. Travis LB, Fosså SD, Schonfeld SJ, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst. 2005;97:1354–65.CrossRefGoogle Scholar
  47. Travis LB, Beard C, Allan JM, Dahl AA, Feldman DR, Oldenburg J, Daugaard G, Kelly JL, Dolan ME, Hannigan R, Constine LS, Oeffinger KC, Okunieff P, Armstrong G, Wiljer D, Miller RC, Gietema JA, van Leeuwen FE, Williams JP, Nichols CR, Einhorn LH, Fosså SD. Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst. 2010;102:1114–30.Google Scholar
  48. Warde P, Specht L, Horwich A, Oliver T, Panzarella T, Gospodarowicz M, von der Maase H. Prognostic factors for relapse in stage I seminoma managed by surveillance: a pooled analysis. J Clin Oncol. 2002; 20:4448–52.Google Scholar
  49. Zengerling F, Kunath F, Jensen K, Ruf C, Schmidt S, Spek A. Prognostic factors for tumor recurrence in patients with clinical stage I seminoma undergoing surveillance – a systematic review. Urol Oncol. 2017. pii: S1078-1439(17)30331-9.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of UrologyFederal Armed Forces HospitalUlmGermany

Section editors and affiliations

  • Chris Protzel
    • 1
  • Axel Heidenreich
    • 2
  1. 1.Universitätsklinikum Rostock, Urologische Klinik und PoliklinikRostockGermany
  2. 2.Division of Oncological Urology, Department of UrologyUniversity of KölnKölnGermany

Personalised recommendations